FHTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FHTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-06-07), Foghorn Therapeutics's Intrinsic Value: Projected FCF is $0.00. The stock price of Foghorn Therapeutics is $6.01. Therefore, Foghorn Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Foghorn Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:
The historical data trend for Foghorn Therapeutics's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Foghorn Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Foghorn Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Foghorn Therapeutics (NAS:FHTX) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Foghorn Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 6.01 | / | ||
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Foghorn Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Alfonso Quintas Cardama | officer: Chief Medical Officer | C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
Samuel Agresta | officer: Chief Medical Officer | 784 MEMORIAL DR., CAMBRIDGE MA 02139 |
Lynch Thomas J. Jr. | director | 800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519 |
B Lynne Parshall | director | 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Carlos Costa | officer: Chief People Officer | C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Fanny Cavalie | officer: Chief Strategy/Bus Ops Officer | C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Ian F Smith | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Michael Lacascia | officer: Chief Legal Officer | 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Carl Decicco | officer: Chief Scientific Officer | 100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142 |
Flagship Ventures Opportunities Fund I General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Abu Dhabi Investment Authority | 10 percent owner | 211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000 |
Michael Mendelsohn | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Adam Koppel | director | C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116 |
Steven F. Bellon | officer: See Remarks | 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Jose Baselga | director | 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
From GuruFocus
By sperokesalga sperokesalga • 03-01-2023
By sperokesalga sperokesalga • 05-08-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 11-22-2022
By Value_Insider Value_Insider • 10-26-2022
By PRNewswire PRNewswire • 05-03-2023
By Value_Insider Value_Insider • 10-27-2022
By Marketwired • 09-05-2023
By GuruFocus Research • 11-03-2023
By Marketwired • 08-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.